A1 Refereed original research article in a scientific journal
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Authors: White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators
Publisher: MASSACHUSETTS MEDICAL SOC
Publication year: 2013
Journal: New England Journal of Medicine
Journal name in source: NEW ENGLAND JOURNAL OF MEDICINE
Journal acronym: NEW ENGL J MED
Number in series: 14
Volume: 369
Issue: 14
First page : 1327
Last page: 1335
Number of pages: 9
ISSN: 0028-4793
DOI: https://doi.org/10.1056/NEJMoa1305889
Abstract
ConclusionsAmong patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.)
ConclusionsAmong patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.)
UTU Research Portal